CKD Stages Explained: eGFR, Albuminuria, and What Each Stage Means

Short Answer

Chronic kidney disease (CKD) is staged on two axes at the same time, because the kidneys can lose filtering capacity and leak protein in different patterns. The first axis is eGFR — an estimate of how well your kidneys filter blood. It gives the kidney-function categories G1–G5: G1 ≥90, G2 60–89, G3a 45–59, G3b 30–44, G4 15–29, and G5 <15 mL/min/1.73 m². In plain English: G1–G2 means filtration is still normal or only mildly reduced, but there must be another marker of kidney damage for it to count as CKD; G3a–G3b means moderate loss; G4 means severe loss; and G5 means kidney failure. (GFR categories per KDIGO, as summarized by NCBI/NIDDK.)

The second axis is albuminuria — how much albumin, a blood protein, is leaking into the urine. It is usually checked with a urine albumin-to-creatinine ratio (ACR or UACR). The commonly used categories are A1 <30 mg/g (<3 mg/mmol), A2 30–300 mg/g (3–30 mg/mmol), and A3 >300 mg/g (>30 mg/mmol). More albumin in urine usually means the kidney's filtering barrier is under more stress or damage, even if eGFR has not dropped much yet. (Albuminuria categories per KDIGO, as summarized by NCBI.)

That is why "stage 3 kidney disease" is not the whole picture. G3a A1 and G3a A3 have the same eGFR band, but they do not carry the same risk profile. Guidelines classify CKD by cause, GFR category, and albuminuria category because albuminuria adds risk information beyond filtration alone. NICE also presents CKD prognosis as a grid that combines G category and ACR category, not a single linear ladder. (See the KDIGO 2024 primer.)

So the short answer is: CKD stages are not just "1 through 5." They are better read as a combined label such as G2 A3, G3a A2, or G4 A1. A clinician confirms the diagnosis and stage using blood and urine tests over time; early kidney disease often has no symptoms, and testing is the only way to know how well the kidneys are working. Welltory does not measure creatinine, eGFR, or albuminuria, and cannot stage or diagnose CKD — it can only help you keep nearby context, such as heart-rate patterns and blood-pressure readings you log manually, in one place for your appointments. (On testing, see NIDDK.)

CKD stages at a glance (eGFR / GFR categories)

CKD stages are not just "stage 1 to stage 5." Clinicians usually describe kidney status with a G category for filtration and an A category for albumin in the urine. The table below is the G side: your estimated glomerular filtration rate, or eGFR, in mL/min/1.73 m². These ranges match the KDIGO-style GFR categories used in NCBI/NIDDK and NICE materials. (GFR categories per NCBI/KDIGO.)

The most important nuance is at the top of the table. G1 and G2 do not automatically mean CKD. If your eGFR is 60 or higher, clinicians look for another sign that the kidneys are being injured — most often albumin leaking into the urine, but sometimes blood or sediment in urine, electrolyte problems from tubular disorders, imaging changes, biopsy findings, or a kidney transplant history. NICE defines CKD as kidney-function or kidney-structure abnormalities present for more than 3 months, or GFR below 60 on at least 2 occasions separated by at least 90 days. (See NICE NG203.)

So a result like G2A1 can mean something very different from G2A3. Same eGFR range, different urine-albumin signal, different risk conversation. This is why your clinician usually reads eGFR together with urine ACR, not as a single number in isolation. NIDDK also frames kidney checks as two tests: a blood test for GFR and a urine test for albumin, because albumin in urine is a sign that kidney filters may be damaged. (See NIDDK.)

Albuminuria categories (ACR)

Albuminuria tells you whether the kidney filter is leaking albumin, a blood protein that should mostly stay in your bloodstream. The usual test is urine albumin-to-creatinine ratio, or ACR/UACR, from a spot urine sample. eGFR tells you how much filtering capacity is estimated to remain; ACR tells you how "leaky" the filter is. That is why CKD staging uses both axes, not eGFR alone. (See NIDDK on urine albumin.)

These cut-offs come from the KDIGO albuminuria categories: A1 is below 30 mg/g, A2 is 30–299 mg/g, and A3 starts at 300 mg/g; the mg/mmol values are rounded category equivalents. (See NCBI/KDIGO albuminuria table.)

In plain terms: anything above 30 mg/g is usually treated as higher than normal and should be interpreted with your clinician, especially if it persists on repeat testing. A one-off high result can happen with things like infection, fever, heavy exercise, or contamination, so clinicians often confirm it rather than staging CKD from one urine result alone. (See NIDDK on albuminuria.)

Why CKD is staged on two axes, not one

CKD is not staged as a simple ladder where "stage 3" tells the whole story. It is staged more like a risk map. One axis is filtration — your estimated glomerular filtration rate, or eGFR, grouped from G1 through G5, with G3 split into G3a and G3b. The other axis is albuminuria — how much albumin, a blood protein, is leaking into the urine, grouped as A1, A2, or A3 by the urine albumin-to-creatinine ratio. NICE guidance explicitly uses the combination of GFR and ACR categories to describe risk, including CKD progression, acute kidney injury, cardiovascular events, and mortality. (See NICE NG203.)

That second axis matters because albumin in urine is not just "extra information." It is a sign that the kidney's filtering barrier is under stress or damaged. Two people can have the same eGFR — the same apparent filtering level — but very different futures if one has little albumin in the urine and the other has a persistent leak. Large CKD Prognosis Consortium meta-analyses found that eGFR and albuminuria have independent and combined associations with outcomes such as mortality and end-stage kidney disease, which is why prognosis changes as albuminuria rises even when eGFR looks similar. (See the CKD Prognosis Consortium meta-analysis.)

So a fuller CKD description reads like "G3a A2" rather than just "stage 3." The "G" tells you roughly how much filtering capacity is estimated to remain. The "A" tells you how leaky the kidney filter is. Your clinician uses both together because CKD risk lives in the combination, not in either number alone.

How eGFR is estimated — and why one number can mislead

eGFR is estimated, not measured directly. That one letter matters. Your lab is not watching blood move through the tiny filters inside your kidneys in real time; it is using an eGFR calculation formula to infer filtering capacity from blood markers such as creatinine and/or cystatin C, along with factors such as age and sex. NIDDK notes that eGFR is an estimate, not a precise measure of kidney function, and that trends over time are often more useful than a single point estimate. (See NIDDK eGFR calculators.)

A large individual-level meta-analysis from the Chronic Kidney Disease Prognosis Consortium looked at why creatinine-based and cystatin-C–based estimates can point in different directions. As the authors put it: "Estimated glomerular filtration rates (eGFRs) can differ according to whether creatinine or cystatin C is used for the eGFR calculation, but the prevalence and importance of these differences remain unclear." (CKD Prognosis Consortium meta-analysis, PMC12595547)

The practical takeaway: a single eGFR from a single creatinine draw is a snapshot, not a verdict. Creatinine can be affected by things that are not kidney damage itself, such as muscle mass and other non-GFR factors, so the number has to be read in context. When accuracy matters — for example, if your result is near a treatment or drug-dosing decision point — NIDDK says using both creatinine and cystatin C is preferred and more accurate than using creatinine alone. (See NIDDK eGFR equations for adults.)

This is why clinicians usually look for persistence, pattern, and the matching urine result before assigning meaning to a stage. CKD is generally diagnosed when kidney damage and/or decreased kidney function has been present for more than 3 months; the two key markers are eGFR and urine albumin. An online eGFR calculator — even a reputable one — can help you understand the estimate to discuss with your clinician. It cannot diagnose CKD by itself. (See NIDDK on evaluating CKD.)

What actually drives CKD progression

CKD usually progresses when the kidney's filters are put under pressure they can't recover from day after day. Two of the biggest, most modifiable drivers are blood pressure and diabetes. High blood pressure can narrow and weaken blood vessels inside the kidneys; damaged kidney vessels then filter less well, leaving extra fluid in the bloodstream, which can push blood pressure even higher. Diabetes adds another route of injury: high blood sugar can damage the tiny kidney blood vessels and nephrons, and many people with diabetes also develop high blood pressure. That is why CKD care often focuses less on "the stage number" alone and more on controlling the forces that keep injuring the filters. (See NIDDK on high blood pressure and kidney disease.)

On blood pressure, a cost-effectiveness modeling study of youth with mild-to-moderate CKD stated the mechanism plainly: "Intensive blood pressure (BP) control in youth with chronic kidney disease (CKD) slows progression, delaying the need for kidney replacement therapy (KRT)." The study modeled intensive BP control over a 5-year horizon and found that better BP control was expected to delay kidney replacement therapy. That does not mean every person should aim for the same BP target or use the same medication plan. It means blood pressure is not just a "heart number" in CKD — it is one of the main mechanical loads your kidneys have to survive. (Cost-effectiveness study in youth with CKD, PMC11796311)

Hypertension and kidney disease also reinforce each other. A clinical overview of hypertension in chronic renal failure described the link this way: "Hypertension is highly prevalent among patients with chronic kidney disease (CKD), contributing significantly to cardiovascular morbidity and progressive renal decline." The same overview lists the drivers behind that link — "volume overload, renin-angiotensin-aldosterone system (RAAS) activation, sympathetic overactivity, and vascular dysfunction." (Hypertension in chronic renal failure overview, PMC12897971)

In plain language: when kidneys lose filtering capacity, the body may hold on to more sodium and fluid, blood vessels may stay tighter, stress-signaling from the nervous system may stay turned up, and the RAAS hormone system may keep telling the body to retain salt and raise vascular pressure. The result can be a loop: CKD raises blood pressure, higher blood pressure damages kidney vessels, and the damaged kidneys become even worse at regulating fluid and pressure.

That RAAS pathway is exactly why blood-pressure medicines that act on it are central to CKD care — but which drug, and whether it is appropriate for you, is a clinical decision made by your clinician. NIDDK notes that ACE inhibitors and ARBs can help slow kidney damage in people with diabetic kidney disease and high blood pressure, and that blood-pressure-lowering medicines can significantly slow CKD progression in some people. They also affect kidney function and potassium, so they need lab monitoring, not guesswork. (See NIDDK on diabetic kidney disease.)

Do not start, stop, or change any blood-pressure or kidney medication based on this article. RAAS-acting drugs (such as ACE inhibitors and ARBs) affect kidney function and potassium and require clinician supervision and monitoring — decisions about them belong to your nephrologist or prescribing clinician.

Complications that track with later stages

As eGFR falls, CKD becomes less of a quiet lab finding and more of a whole-body condition. NIDDK notes that complications become more common and more severe as eGFR declines. That is why later stages are monitored for cardiovascular disease, anemia, mineral-and-bone disorder, malnutrition, depression, and reduced functional status — not just for a lower filtration number. Fluid and salt retention can also show up, often driving blood pressure higher; if extra fluid builds up in the lungs, it can cause shortness of breath. (See NIDDK on CKD complications.)

To put the risk in context: in a cohort of 170 people with biopsy-proven malignant-hypertension–associated kidney injury who were not dialysis-dependent at baseline, progression to kidney failure was substantial over follow-up — "52 patients (30.6%) progressed to end-stage renal disease (ESRD)." This is a specific, higher-risk group, not the average person with early CKD. (Long-term renal outcomes cohort, PMC12833902)

That does not mean every person in a later CKD stage will develop every complication. It means the body has less reserve. Healthy kidneys do more than filter waste: they help control fluid, blood pressure, red blood cell production, and mineral balance for bone health. When those jobs falter, fatigue from anemia, weaker bones or fracture risk, cardiovascular strain, swelling, breathlessness from fluid overload, and day-to-day functional limits can become part of the care plan. (See Johns Hopkins on chronic kidney disease.)

Living with CKD and tracking it

Living with CKD is partly about knowing what you can track — and what you cannot. Kidney function is tracked with clinician-ordered tests: eGFR from a blood test, and albumin or ACR/UACR from a urine test. Those numbers show how well your kidneys are filtering blood and whether protein is leaking into urine, which is why they are used to monitor CKD over time and to check whether treatment is helping. (See NIDDK on tests and diagnosis.)

The schedule is personal. Your care team may check eGFR and ACR more or less often depending on your CKD stage, albuminuria level, diabetes, blood pressure, recent changes in results, medication changes, illness, or risk of progression. NICE recommends agreeing the monitoring frequency with the person who has CKD, and tailoring it rather than treating every patient the same. (See NICE NG203 guidance.)

A consumer wearable cannot measure creatinine, albumin, eGFR, ACR, or CKD stage. It cannot tell you whether your kidneys are filtering better or worse. What it can do is help you keep nearby context in one place: resting heart rate, HRV trends, sleep, activity, symptoms, and blood pressure values you enter from a proper cuff. Blood pressure matters because high blood pressure can damage kidneys, and controlling it is one of the main ways clinicians try to protect kidney function. (See NIDDK on managing CKD.)

Use that data as appointment context, not as a diagnosis. A useful CKD journal might include your lab dates and results, home blood pressure readings, medication changes, swelling, shortness of breath, appetite changes, fatigue, new pain, infections, and questions for your clinician. The goal is not to "stage yourself" from an app. The goal is to help your care team see the pattern between visits — what changed, when it changed, and what was happening in your body at the time. Welltory does not measure kidney function; the heart-rate and blood-pressure context it holds is a qualitative aid for those conversations, not a filtration, albuminuria, or staging claim.

Red flags — when to seek urgent care

This is a general educational list, not a substitute for medical advice. Get urgent medical help — or call emergency services if symptoms are severe — if your kidneys suddenly seem to stop "clearing" fluid: you pass very little urine or none at all, your legs, ankles, hands, or face swell quickly, or you become short of breath, especially when lying down. These can happen when fluid and waste products build up faster than your body can compensate. Acute kidney failure can include little or no urine, swelling, shortness of breath, blood in the urine, flank pain, confusion, and seizures; CKD can also cause swelling and shortness of breath when kidney function has worsened. (See MedlinePlus on acute kidney failure.)

Treat chest pain, severe shortness of breath, new confusion, extreme drowsiness, fainting, or any seizure as an emergency — seek immediate medical attention or call emergency services. These symptoms can mean the problem is no longer just "a kidney number" on a lab report — it may be affecting your lungs, brain, heart rhythm, or blood chemistry. (See MedlinePlus on acute kidney failure.)

Also seek same-day urgent care for visible blood in your urine, or for severe pain in your side, flank, or lower back — especially if you also have fever, chills, nausea, vomiting, painful urination, or feel rapidly worse. Kidney infection can cause fever, bloody or foul-smelling urine, and pain in the back, side, or groin, and NIDDK advises seeking care right away because a kidney infection can sometimes progress to sepsis. (See NIDDK on kidney infection.)

If you measure a very high blood pressure reading — around 180/120 mm Hg or higher — and you also have chest pain, shortness of breath, back pain, weakness or numbness, trouble speaking, severe headache, confusion, or vision changes, call emergency services immediately. That pattern can signal a hypertensive emergency, where high pressure may be damaging organs, including the kidneys, brain, heart, or eyes. (See American Heart Association on when to call 911.)

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data